Polycystic ovarian syndrome (PCOS) is a multifactorial and polygenic condition. It is a syndrome of ovarian dysfunction that is characterized by anovulation, hyperandrogenism and/or the presence of polycystic ovary (PCO) morphology.
INTRODUCTION
Polycystic ovarian syndrome (PCOS) is a multifactorial and polygenic condition. It is a syndrome of ovarian dysfunction that is characterized by anovulation, hyperandrogenism and/or the presence of polycystic ovary (PCO) morphology.
The PCOS is one of the most common female endocrinopathies affecting 6%-7% of women in reproductive age. In the past the clinical diagnosis rested on the triad of hirsutism, amenorrhoea and obesity. The diagnosis of PCOS is based on the Rotterdam criteria: presence of any two of (i) chronic anovulation; (ii) clinical/ biochemical parameters for hyperandrogenism; and (iii) polycystic ovaries on ultrasonography. 1 Subsequently it has been recognized that PCOS has an extremely heterogeneous clinical picture and is multifactorial in aetiology. PCOS may represent the largest under-appreciated segment of the female population at risk of cardiovascular disease. The pathophysiology is complex involving the hypothalamo-pituitaryovarian axis, ovarian theca cell hyperplasia, hyperinsulinaemia and a multitude of other cytokine and adipocyte-driven factors. 2 Insulin resistance, hyperandrogenism and dyslipidaemia are likely to be the major risk factors for cardiovascular diseases (CVD) in women with PCOS. 3, 4 Insulin resistance and dyslipidaemia seem to have an important role on the risk of cardiovascular pathology in women with PCOS. It is still not known to what degree dyslipidaemia contributes to this risk. 5 Generally, dyslipidaemia of PCOS is characterized by increased triglycerides and low high density lipoprotein (HDL) cholesterol, but it has also been found that although low HDLcholesterol is common, hypertriglyceridaemia is relatively uncommon. 6 On the contrary, the most classic lipid alteration determining cardiovascular risk, increase of low density lipoprotein (LDL) cholesterol, is not common in all populations with PCOS. Beyond LDLcholesterol concentrations, the quality of LDL may exert a direct influence on the cardiovascular risk.
Although for many years it has been known that PCOS is associated with reproductive morbidity and increased risk for diabetes mellitus, ovarian and endometrial cancer, more recently a large number of studies have shown that women with PCOS also bear an increased cardiovascular risk. 6 Lipoprotein(a) [Lp(a)] is a modified form of LDL in which apo A-1 is bound to apo B. It is metabolically distinct from LDL and its levels are determined genetically, with its concentration remaining stable throughout the life of a subject. Changes in plasma lipid and Lp(a) composition places the patient at an increased risk for CVD. High Lp(a) levels represent an independent risk factor for cardiovascular events, linked to an increased risk of myocardial infarction, stroke and coronary heart disease. 7 Early screening of modifiable cardiovascular risk factors may help in preventing development of cardiovascular disease. So, our study is done to find out if there is an elevated Lp(a) level and dyslipidaemia in PCOS. The objective of the study was to assess Lp(a) and lipid profile levels in women with PCOS.
MATERIAL AND METHODS
The study was carried out on 30 newly diagnosed PCOS patients (age range 18-35 years) based on Rotterdam criteria 1 Five mL peripheral venous blood sample was obtained after overnight fasting of 12 hours by venepuncture from both cases and controls and the serum was separated. Estimation of serum Lp(a) was performed by immunonephelometric method. Total cholesterol (TC), serum triglycerides (TG), HDL cholesterol, fasting blood glucose, blood urea, serum creatinine were estimated using commercial kits on A25 auto analyzer (Biosystems, Spain). Serum very low density lipoprotein (VLDL) cholesterol and LDL cholesterol were calculated from the values of TC, TG and HDL cholesterol by applying Friedewald's formula. 8 TC/HDL cholesterol and LDL cholesterol/HDL cholesterol ratios were determined.
Statistical analysis
Comparisons between groups were performed using the Mann-Whitney U-test. Comparison of proportions of parameters was done using Chi-square test. Correlation was tested using Pearson's correlation coefficient. SPSS software version 13.0, SPSS Inc., Chicago, USA was used for statistical analysis. A p value < 0.05 was considered statistically significant.
RESULTS
The parameters studied are shown in Table 1 . Correlations are shown in Table 2 . There was no statistically significant difference in age and BMI between cases and controls. TC, TG, LDL cholesterol, HDL cholesterol, VLDL cholesterol, TC/HDL cholesterol and LDL cholesterol/HDL cholesterol also did not show significant difference between cases and controls. Median Lp(a) levels in patients with PCOS were similar compared to control subjects (p = 0.273). The proportion of patients with Lp (a) greater than 30 mg/dL was higher in patients with PCOS compared to control subjects (33% Vs 10%; p = 0.028). A positive correlation was observed between Lp(a) and BMI (p = 0.016), TC (p = 0.001) and LDL cholesterol (p = 0.010) ( Table 2) .
DISCUSSION
PCOS is the most common endocrine disorder to affect women. It is a genetically complex disorder that is characterized by hyperandrogenemia and amenorrhoea or oligomenorrhoea resulting in infertility among reproductive age women. Cardinal features of PCOS include chronic anovulation, clinical or biochemical hyperandrogenism, obesity and polycystic ovaries.
Obesity, insulin resistance and hyperinsulinaemia are commonly associated with recognized increased risk for the development of metabolic syndrome and diabetes mellitus. The metabolic syndrome is a cluster of risk factors for the development of CVD.
We did not find any significant difference in TC, TG, LDL cholesterol, HDL cholesterol, VLDL cholesterol, TC/HDL cholesterol and LDL cholesterol/HDL cholesterol in patients with PCOS and control subjects. However, higher TG, TC and LDL cholesterol, lower HDL cholesterol and apoA-I were observed in PCOS patients in another study. 9 A higher mean TC/ HDL cholesterol and LDL cholesterol/HDL cholesterol were observed in PCOS compared to controls in another study. 10 Low HDL (<50 mg/dL) as a component of dyslipidaemia was observed in 86.7% of cases in our study. This is similar to the findings in south Indian population where low HDL was seen 93.3% cases with PCOS. 11 The reason for dyslipidaemia in PCOS may be attributed to hyperinsulinaemia and hyperandrogenemia. This causes adipocytes to undergo increased catecholamine-induced lipolysis and release of free fatty acids into the circulation. Increased free fatty acids in the liver stimulate secretion of VLDL which ultimately leads to hypertriglyceridaemia. 12 Through the reverse cholesterol transport pathway, hypertriglyceridaemia leads to low HDL cholesterol and increased LDL cholesterol levels. Further priming of adipocytes by androgens in early life predisposes to the dyslipidaemia associated with PCOS. Conversely, it is also possible that hyperandrogenaemia is a consequence of more metabolically active adipocytes. 13 Hyperandrogenism may also affect lipid metabolism by the induction of hepatic lipase activity which has a role in the catabolism of HDL particles. 11 Insulin resistance has been associated with decreased levels of HDL cholesterol and increased levels of LDL cholesterol and TG.
This has been associated with increased risk of CAD.
14 Lp(a) greater than 30 mg/dL has been considered as elevated. 15 Although the median Lp(a) was higher in cases than in controls, the difference was not statistically significant (p = 0.273). However, our study showed a significantly higher number of cases with Lp(a) >30 mg/dL (33% in cases Vs 10% in controls) when compared to the controls (p = 0.028). Our results are in agreement with observation from another study 3 where higher circulating asymmetric dimethylarginine (ADMA), total homocysteine, high sensitive C-reactive protein (hsCRP), Lp(a) and fibrinogen were observed in PCOS than in healthy controls.
Studies were conducted to find out other lipids promoting arteriosclerosis in women with PCOS. Apoprotein B (ApoB) is the main structural component of LDL and its evaluation represents a more accurate measurement of the relative number of LDL particles compared to the more common measurement of LDL cholesterol. One study 5 did not find a difference in apoB levels between women with PCOS and the controls. This they attributed to genetic and environmental factors that determine different lipid patterns. Lipoprotein(a) is a heterogeneous class of lipoproteins, metabolically distinct from LDL and its levels are determined genetically. High Lp(a) levels represent an independent risk factor for cardiovascular events. Their study showed a quarter of the 
